Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Anaptysbio Inc (ANAB)

Anaptysbio Inc (ANAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
A colorful concept image of a scoring system_ Image by Who is Danny via Shutterstock_
This Biotech Stock Has More Than Tripled in 2025, but Red Flags Are Waving Barchart - Fri Dec 19, 11:05AM CST

AnaptysBio (ANAB) has surged 227% over the past year, hitting a 5-year high. Shares have strong technical momentum and a 100% “Buy” opinion from Barchart. Analyst sentiment remains bullish, but Wall...

ANAB : 50.01 (-0.06%)
Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis PR Newswire - Mon Dec 15, 6:00AM CST

WASHINGTON , Dec. 15, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration...

ANAB : 50.01 (-0.06%)
VNDA : 6.91 (+1.02%)
Anaptys Announces Participation in December Investor Conferences GlobeNewswire - Tue Nov 25, 3:15PM CST

SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel...

ANAB : 50.01 (-0.06%)
Anaptys Announces $100 Million Stock Repurchase Plan GlobeNewswire - Fri Nov 21, 3:00AM CST

SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its...

ANAB : 50.01 (-0.06%)
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary GlobeNewswire - Fri Nov 21, 2:50AM CST

SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced it has filed a...

ANAB : 50.01 (-0.06%)
Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis GlobeNewswire - Mon Nov 10, 8:00AM CST

Rosnilimab was safe and well tolerated with similar adverse event rates vs . placebo Observed expected pharmacology, including ~90% depletion of pathogenic T cells, however lack of adequate efficacy...

ANAB : 50.01 (-0.06%)
Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update GlobeNewswire - Tue Nov 4, 3:15PM CST

Announced intent to separate biopharma operations from substantial royalty assets by YE 2026 Phase 2 top-line data through Week 12 for rosnilimab, a pathogenic T cell depleter, in ulcerative colitis on...

ANAB : 50.01 (-0.06%)
Anaptys Announces Participation in November Investor Conferences GlobeNewswire - Tue Nov 4, 3:15PM CST

SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel...

ANAB : 50.01 (-0.06%)
Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation GlobeNewswire - Wed Oct 29, 8:15AM CDT

New data reinforce rosnilimab’s efficacy profile in rheumatoid arthritis (RA) with deepening of clinical responses, including CDAI remission, from Week 12 to Week 28 regardless of prior advanced therapy,...

ANAB : 50.01 (-0.06%)
Truist Financial Reaffirms Their Hold Rating on AnaptysBio (ANAB) Tipranks - Thu Oct 16, 6:58AM CDT

In a report released today, Joon Lee from Truist Financial maintained a Hold rating on AnaptysBio. The company’s shares closed yesterday at $31.85.Elevate Your Investing Strategy: Take advantage of TipRanks...

ANAB : 50.01 (-0.06%)

Barchart Exclusives

Have a MERRY Christmas With These 9 Unusually Active Options Barchart - Thu Dec 25, 12:30PM CST
In the past year, there have been many interesting stocks and their unusually active options to discuss. Whether you do or don’t celebrate Christmas, here are nine stocks whose unusually active options make for good bets in 2026. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot